{"id":"NCT02818998","sponsor":"Bayer","briefTitle":"Efficacy and Safety of Three Different Aflibercept Regimens in Subjects With Diabetic Macular Edema (DME)","officialTitle":"An Open-label, Randomized, Active-controlled, Parallel-group, Phase-3b Study of the Efficacy, Safety, and Tolerability of Three Different Treatment Regimens of 2 mg Aflibercept Administered by Intravitreal Injections to Subjects With Diabetic Macular Edema (DME)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-11-16","primaryCompletion":"2018-11-13","completion":"2019-09-24","firstPosted":"2016-06-30","resultsPosted":"2019-12-04","lastUpdate":"2020-07-31"},"enrollment":463,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Macular Edema"],"interventions":[{"type":"DRUG","name":"Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)","otherNames":[]}],"arms":[{"label":"Aflibercept 2 mg fixed","type":"EXPERIMENTAL"},{"label":"Aflibercept 2 mg flexible","type":"EXPERIMENTAL"},{"label":"Aflibercept 2 mg PRN","type":"EXPERIMENTAL"}],"summary":"To evaluate the efficacy of long-term treatment with 2 mg aflibercept via different intravitreal (IVT) treatment regimens to participants with DME pretreated with 2 mg aflibercept every 8 weeks after 5 initial monthly injections for approximately 1 year or more (according to the EU label for the first year of treatment)","primaryOutcome":{"measure":"Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) at Week 52","timeFrame":"From baseline to Week 52","effectByArm":[{"arm":"Aflibercept 2 mg Fixed","deltaMin":0.4,"sd":6.7},{"arm":"Aflibercept 2 mg Extended","deltaMin":0.5,"sd":6.7},{"arm":"Aflibercept 2 mg PRN","deltaMin":1.7,"sd":6.8}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"},{"comp":"OG000 vs OG002","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":9},"locations":{"siteCount":64,"countries":["Austria","Canada","Czechia","France","Germany","Hungary","Italy","Lithuania","Poland","Portugal","Slovakia","Spain","Switzerland","United Kingdom"]},"refs":{"pmids":["35412227"],"seeAlso":["https://clinicaltrials.bayer.com/","http://www.clinicaltrialsregister.eu/"]},"adverseEventsSummary":{"seriousAny":{"events":35,"n":155},"commonTop":["Cataract","Visual acuity reduced","Diabetes mellitus","Diabetic retinopathy","Nasopharyngitis"]}}